Idarubicin Injection 5 mg/5 mL (3)

Land: Australia

Språk: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv ingrediens:

idarubicin hydrochloride, Quantity: 1 mg/mL

Tilgjengelig fra:

Pfizer (Perth) Pty Ltd

Legemiddelform:

Injection, intravenous infusion

Sammensetning:

Excipient Ingredients: glycerol; hydrochloric acid; water for injections

Administreringsrute:

Intravenous Infusion

Enheter i pakken:

1 X 5 mL

Resept typen:

(S1) This Schedule is intentionally blank

Indikasjoner:

SOUTH AFRICA: Acute non-lymphocytic leukaemia (ANLL), including acute myeloblastic leukaemia (AML) in adults, for remission induction as front-line therapy, or for remission induction in relapsed or refractory patients. ZAVEDOS, in combination with cytarabine, is indicated for the first remission induction-line treatment of previously untreated children with acute myeloid leukaemia (AML)

Produkt oppsummering:

Visual Identification: Red-orange, clear, mobile solution; Container Type: Vial; Container Material: PP; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Autorisasjon status:

Listed (Export Only)

Autorisasjon dato:

2023-02-17